Immune checkpoint inhibitors (ICIs) such as anti-CTLA-4 and anti-PD-(L)1 have revolutionized cancer treatment, providing proof that pharmacological intervention can enhance the body’s own tumor control. However, large successes for these agents are limited to “hot tumors,” tumors that have an active immune component where checkpoint inhibition can reinvigorate a subpar immune response.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Nigel P.
Contact Nigel P., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack